SightfileU.S. market data from official filings

Companies › ACRS

ACLARIS THERAPEUTICS (ACRS)

Institutional ownership, SEC filings and insider activity

Sector: Healthcare & Pharma · SEC CIK 0001557746 · EDGAR filings · Updated 2026-06-08

ACLARIS THERAPEUTICS (ACRS) has reported institutional ownership of 77.8%, with 136 institutional managers holding positions valued at $407.5M per the latest 13F reporting period. SEC filings include an active substantial-doubt (going concern) disclosure per the filings.

Institutional ownership
77.8%
Institutional managers
136
Reported 13F value
$407.5M
Insider activity
40 trans.
$0 net flat
Data flags
1 active
from SEC filings

Latest updates

Institutional ownership overview

According to SEC 13F filings tracked by Sightfile, ACLARIS THERAPEUTICS has 136 institutional holders and institutional ownership of 77.8%.

Insider activity

Insiders reported 40 transactions (0 buys, 0 sells) across 10 reporting insiders, with a net reported value of $0.

Data flags from SEC filings

Active substantial-doubt (going concern) disclosure per the filings, most recently filed 2026-05-07 (recurring since 2020-02-25) — source filing. The authoritative details are those stated in the filing itself.

Related companies

VERASTEM INC (VSTM) · RIGEL PHARMACEUTICALS INC (RIGL) · TECTONIC THERAPEUTIC INC (TECX) · UPSTREAM BIO INC (UPB) · DESIGN THERAPEUTICS INC (DSGN) · LARIMAR THERAPEUTICS INC (LRMR)

See full history, cross-references and alerts on Sightfile
Sightfile provides information only — not investment advice, recommendations, or an assessment of any security. Data is derived from official public sources (SEC EDGAR and U.S. government agencies), may contain errors or delays, and should be verified against the source filing before relying on it.
Data sources: SEC EDGAR (filings, 13F, FTD), aggregated by Sightfile. Page updated 2026-06-08.